OUR PRODUCTS

Dry Eye Syndrome ("Dry Eye")

Multifactorial disease of the tear and ocular surface resulting in discomfort, visual disturbance and tear film instability with potential damage to the ocular surface.*

  • Tear layer protects the surface of the eye, providing nutrition

  • Injury is a dynamic process, resulting in change in tear composition & symptoms of burning, redness, blurred vision, etc.

  • Dry Eye is the most frequent symptom treated by ophthalmologists

  • Epidemiological studies show dry eye will occur in 14-33% of population. Market size in 2014 est. + $2.5B, increasing steadily every year. 

  • Increase in incidence with age and other factor

Conjunctivochalasis (CCh)

  • Conjunctivochalasis (CCh) is a complication of dry eye

  • Aseptic, chronic inflammation of the conjunctiva; on a background of dry eye syndrome

  • Common age-related eye condition over 50; increases in frequency &  severity with age

  • Also markedly increased in people wearing contact lenses, regardless of age

  • Appears in one third of dry eye patients

  • Inflammation condition is sustained; not spontaneously reversible

  • Severe CCh (Stage 3) can only be treated by invasive surgical treatment, which can cause considerable discomfort

Sjögren’s Syndrome

  • Sjögren’s syndrome is a chronic long-term auto-immune disease

  • The patient's white blood cells attack the saliva and tear glands, leading to dry mouth and eyes

  • While Sjögren’s syndrome can develop at any age, the majority of patients are diagnosed after the age of 40 with 90% of patients female

  • There are approximately 4,000,000 people in the USA and 500,000 in the UK with Sjögren’s Syndrome

© 2017 by Wize Pharma Inc. All Rights Reserved.